Last reviewed · How we verify
AML Cell Vaccine
At a glance
| Generic name | AML Cell Vaccine |
|---|---|
| Sponsor | King's College London |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma (PHASE1)
- DC/AML Fusion Cell Vaccine vs Observation in Patients Who Achieve a Chemotherapy-induced Remission (PHASE2)
- Adoptive T Cell Therapy With DC/AML Fusion Vaccine Plus Decitabine and Venetoclax in AML (PHASE1)
- Dendritic Cell/AML Fusion Cell Vaccine Following Allogeneic Transplantation in AML Patients (PHASE1)
- Study Evaluating Safety and Efficacy of UCART123v1.2 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (PHASE1)
- Covid-19 Long Haul Preventative and Health Promotion Care Clinical Trial Acceleration Program. (PHASE4)
- WT1 Vaccine Treatment of Patients in Remission From Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL) (PHASE2)
- Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AML Cell Vaccine CI brief — competitive landscape report
- AML Cell Vaccine updates RSS · CI watch RSS
- King's College London portfolio CI